Edinburgh Molecular Imaging (EMI), a spin-out of the Scottish capital’s university, has raised £4m ($6.5m) from venture firm Epidarex Capital. The funding will be used to further develop EMI’s imaging technology, used to diagnose and monitor diseases. EMI’s current focus is on lung conditions such as cancer and fibrosis, but will eventually be expanded to…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
